Breastfeeding · Safety-first · 2026
Start from the labels, and read them properly: the injectable products do not tell you to stop nursing. They report no human-milk data for semaglutide — Zepbound actually prints a milk study — and ask that the benefits of breastfeeding be weighed against your need for the medicine. Breastfeeding is not recommended with Wegovy tablets, Rybelsus or Foundayo. So this isn't a ranking of what's “safe” in milk — it's a ranking of who handles the conversation responsibly: oversight, a real feeding-status conversation, and on-label options where they help.
The short answer
No GLP-1 is labeled safe for nursing, but none of the injectables is labeled off-limits either — so this is a judgment call to make with a clinician, not a rule to look up. CoreAge Rx, a featured partner, scores 86/100; its clinicians raise feeding status, washout, and contraception before writing. Providers with on-label brand access score well too, for the manufacturer's own lactation labeling — but none of that makes a GLP-1 recommended while you nurse.
5 providers. CoreAge Rx is a featured partner; providers we work with may appear first. The Metabolic-Fit Score is printed on every row so you can check it.
CoreAge's officially linked public offer advertises compounded semaglutide at $79/month and tirzepatide at $129/month across doses, with care and overnight shipping included. It describes one-time purchases without a required subscription. Main navigation still shows semaglutide from $99; confirm your prescription quantity and total, and read the refund limits before paying.
Semaglutide from $129 and tirzepatide from $179 a month, all doses included — a reasonable option if you can live with a yearly plan, a month-to-month price you only see at checkout, and a pharmacy it doesn't name.
The closest thing here to a real obesity-medicine clinic online — board-certified physicians and registered dietitians, monthly video visits, and a real effort to work brand-name drugs through insurance. The $299 self-pay fee is for that clinical team, not the medication.
A women's-health practice first and a GLP-1 prescriber second: an OB-GYN or nurse practitioner, a registered dietitian and hormone labs on every case, check-ins every one to two weeks, and brand-name options from the Wegovy tablet to Zepbound. The $149 a month buys the care team, not the medication, which your own pharmacy and insurance price. Full care runs in 45 states plus DC; five more states get nutrition-only care with no prescribing.
| # | Provider | From | Score | |
|---|---|---|---|---|
| 1 | CoreAge Rx | $79/mo | See review | 86 · B |
| 2 | Gala Health | See review | All 50 states | 84 · B |
| 3 | Form Health | See review | See review | 86 · B |
| 4 | Ro | See review | See review | 84 · B |
| 5 | Allara Health | See review | 45 states | 81 · B− |
Milk-transfer findings do not establish infant safety. Injectable semaglutide labels describe missing human-milk data. Zepbound includes a small milk-transfer study but no data on infant effects or milk production. These labels ask the clinician and patient to weigh breastfeeding benefits and clinical need. Breastfeeding is not recommended with Wegovy tablets, Rybelsus or Foundayo. Discuss your exact formulation, feeding plans and medical history with your clinician.
Three things, and they're what the Metabolic-Fit Score weights: a real clinician who asks about feeding status and future-pregnancy plans; the ability to sequence treatment for after weaning; and, for some mothers, access to on-label brand products that carry the manufacturer's own lactation labeling. CoreAge Rx, a featured partner, scores 86/100; its clinicians raise timing rather than ignoring it.
That's a clinician decision, not a fixed rule. Note the two questions come apart: for tirzepatide there IS a published milk study, while the semaglutide injection label still describes missing human-milk data. Pregnancy is the firmer number — the semaglutide label asks you to stop at least two months before a planned pregnancy, which is the drug's long half-life, not the roughly-a-week-per-dose figure that gets quoted. The usual sequence is: settle feeding plans, settle future-pregnancy plans, then discuss medication with a provider who runs labs.
Because on-label Wegovy and Zepbound carry the manufacturer's own pregnancy and lactation language, which is cleaner to hand to an OB than a compounded product's — and in Zepbound's case that language includes an actual human-milk study. That's one input among several: clinician oversight and a genuine timing conversation still matter most, and no on-label status makes a GLP-1 *recommended* while nursing.
Rankings reflect our published methodology. This page is informational and not medical advice; compounded medications are not FDA-approved brand products, and GLP-1 medicines are not used in pregnancy or while trying to conceive. See our medical disclaimer. Some links here earn us a referral fee, walled off from the score — read our funding disclosure.
Keep exploring
Each board answers a different question a mother brings to GLP-1 care.